Denison Mines Corp Ordinary Shares (Canada) vs Summit Therapeutics Inc — how do they compare? Denison Mines Corp Ordinary Shares (Canada) trades at $2.43 (market cap $2.14B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 6.4× Denison Mines Corp Ordinary Shares (Canada)'s market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Denison Mines Corp Ordinary Shares (Canada) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Denison Mines Corp Ordinary Shares (Canada) for 1 Days and Summit Therapeutics Inc for 16 Days on average.
| DNN | SMMT | |
|---|---|---|
Market Cap | $2.14B | $13.71B |
Volume | 56,727,592 | 6,173,057 |
Sector | Energy | Health |
52-Week High | $4.37 | $26.38 |
52-Week Low | $2.27 | $12.43 |
Typical Hold Time | 1 Days | 16 Days |
Enterprise Value | $1.98B | $13.04B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Denison Mines is a uranium mining, development, and exploration company focused on Canada's Athabasca Basin. Its portfolio includes the Wheeler River project and interests in other uranium projects and processing facilities.
Read more on DNN →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →